By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on Owls Nest's CRVL stake, with concerns about AI-driven margin compression, payer deployments, and structural headwinds, but also seeing potential in the debt-free balance sheet and CERIS platform.
Risk: Payer deployments lagging and AI-driven margin uncertainty
Opportunity: Accelerating top-line growth beyond the current single-digit rate through 'large payer wins'
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Owls Nest acquired 348,329 shares of CorVel last quarter; the estimated trade size was $20.06 million (based on quarterly average prices).
The quarter-end CorVel stake is valued at $19.04 million.
The transaction represented a 7.02% increase in 13F reportable AUM for the period.
On May 14, 2026, Owls Nest Partners IA disclosed a new position in CorVel (NASDAQ:CRVL), acquiring 348,329 shares in an estimated $20.06 million trade based on quarterly average pricing.
According to its SEC filing dated May 14, 2026, Owls Nest Partners disclosed a new holding of 348,329 CorVel shares, with the estimated transaction value pegged at $20.06 million based on average closing prices from January through March. The quarter-end position was valued at $19.04 million, a net change that includes underlying price movement over the period. No prior stake was reported in the previous filing.
NYSE:TGLS: $36.10 million (12.6% of AUM)
As of Friday, CorVel shares were priced at $62.74, down 45% over the past year and well underperforming the S&P 500, which is instead up about 28% in the same period.
| Metric | Value | |---|---| | Revenue (TTM) | $958.5 million | | Net income (TTM) | $110.3 million | | Price (as of market close May 13, 2026) | $62.74 | | One-year price change | (45%) |
CorVel is a leading provider of technology-enabled healthcare management and cost containment solutions, with a focus on the insurance and risk management sector. The company combines advanced analytics and automation to streamline claims processing and deliver value to clients managing complex healthcare and liability exposures. CorVel's strategic emphasis on innovation and operational efficiency positions it as a competitive player in the evolving insurance services landscape.
This purchase looks like a contrarian bet on a business that continues to execute even as the stock has fallen sharply, and CorVel's recent results help explain the appeal. Fiscal 2026 revenue climbed 7% to $959 million, while diluted earnings per share increased 17% to $2.14. Fourth-quarter revenue rose 7% to $249 million, and the company ended the year with $233 million in cash and no debt while continuing to repurchase shares.
Management highlighted growing demand for CERIS, its healthcare payment accuracy platform, noting that several large payer wins should provide greater revenue visibility as those deployments scale. The company also pointed to continued investments in AI, automation, telemedicine, cybersecurity, and data integration across its claims management business.
Ultimately, CorVel sits at the intersection of insurance, healthcare cost management, and AI-enabled workflow automation, and with earnings still growing despite the stock's weakness, Owls Nest may be betting that the market has become too pessimistic about a company quietly producing consistent cash flow and expanding margins.
Before you buy stock in CorVel, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CorVel wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $477,813! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 23, 2026. *
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Drainage Systems and CorVel. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"A single activist-sized purchase does not alter the structural headwinds that drove the 45% drawdown."
Owls Nest's new 348k-share CRVL stake signals conviction in a debt-free firm posting 17% EPS growth on 7% revenue, yet the 45% price drop since last year likely embeds doubts about sustaining CERIS platform wins amid rising AI competition in claims processing. The fund's $19M position equals 6.66% of its AUM, a concentrated bet that ignores CorVel's modest top-line trajectory and potential margin compression if payers delay deployments. Investors should weigh whether cash-flow consistency offsets the narrow moat in a consolidating insurance-services sector.
The 7% revenue growth and recent large-payer wins may already be fully priced in at current multiples, and Owls Nest could simply be averaging into a name whose long-term addressable market is shrinking as insurers build in-house AI tools.
"A 45% stock decline despite 17% EPS growth and fortress balance sheet signals either a multiple re-rating justified by deteriorating competitive moats or client concentration/margin pressure the article omits entirely."
Owls Nest's $20M entry into CRVL at depressed valuations deserves scrutiny beyond 'contrarian bet on execution.' Yes, CRVL grew EPS 17% YoY with $233M net cash and no debt—solid. But the 45% drawdown over 12 months while S&P 500 rose 28% suggests structural headwinds the article doesn't probe: margin compression from AI commoditization, client concentration risk in workers' comp (cyclical, tied to employment), or competitive pressure from larger insurers building in-house automation. Owls Nest's position is only 6.66% of their AUM—material but not conviction-level. The CERIS platform 'wins' are mentioned vaguely; no revenue contribution disclosed. This looks like a value trap dressed as a bargain.
CRVL's 11.5x forward P/E (based on $2.14 EPS and $62.74 price) is genuinely cheap for a 17% EPS grower with zero leverage and $233M cash, and Owls Nest may simply be right that the market overshot on sector rotation fears.
"CorVel's valuation is currently disconnected from its modest 7% revenue growth, suggesting the market is pricing in long-term margin erosion despite the company's clean balance sheet."
Owls Nest Partners’ entry into CorVel (CRVL) at a 45% discount from peak levels looks like a classic value play, but the 17% EPS growth against a 45% stock price drawdown suggests a significant valuation compression. At roughly $62, the stock is trading at a forward P/E of approximately 29x, which is rich for a business growing revenue at only 7% annually. While the debt-free balance sheet and CERIS platform provide a defensive moat, the market is clearly pricing in a structural slowdown or margin pressure that the article ignores. Investors should focus on whether the 'large payer wins' can actually accelerate the top line beyond the current single-digit growth rate.
The market may be correctly identifying that CorVel’s AI-driven cost containment is facing commoditization, making the current valuation a 'value trap' rather than a bargain.
"CorVel could justify a higher multiple if payer deployments scale and AI-driven cost containment yields durable margins; otherwise, the upside hinges on execution, not the valuation."
Owls Nest’s new CRVL stake signals a contrarian bet on a cash-rich, debt-free operator with growth still intact. 2026 revenue +7%, EPS +17%, and CERIS/AI initiatives offer revenue visibility and cost containment upside, while the stock trades around $63 with a trailing ~29x P/E and a sizable cash pile. Yet the piece glosses over real execution risk: payer deployments can lag, AI-driven margins may be uncertain, and the 45% Y/Y drawdown hints at structural concerns. The stake is notable but not a catalyst-killer unless payer wins scale meaningfully and ROIC from new tech is proven.
But the price drop may reflect durable concerns about growth and margin sustainability; without near-term payer wins or visible ROIC from CERIS/AI, the new stake could be a value trap rather than a catalyst.
"P/E mismatch between Claude and Gemini exposes inconsistent growth assumptions that undermine valuation claims."
Claude's 11.5x forward P/E at $2.14 EPS directly contradicts Gemini's 29x reading at similar prices, revealing mismatched assumptions on whether growth is already embedded or eroding. This gap leaves unexamined how the 17% EPS print might shift if CERIS deployments face the in-house AI buildout risks both flag. Reconciling trailing versus forward bases first would strengthen any value-trap or bargain thesis.
"The valuation debate hinges on undisclosed earnings assumptions; without CRVL's own 2026 guidance, both the bargain and trap theses rest on guesswork."
Grok's P/E reconciliation is critical—Claude's 11.5x assumes 2026 forward earnings of ~$5.46/share (implying 155% cumulative growth from $2.14), while Gemini's 29x uses trailing or near-term multiples. Neither disclosed their earnings base. If CRVL's guidance supports Claude's trajectory, the 11.5x is defensible; if not, it's fiction. The article provides zero forward guidance, so both readings are speculative. This gap directly determines whether Owls Nest is early or late.
"The 11.5x forward P/E is a speculative error, and the investment thesis relies on share repurchases rather than organic growth acceleration."
Claude and Gemini are debating a valuation phantom. CorVel’s historical EPS is roughly $2.15–$2.20, making a 29x trailing P/E the only reality-based metric here. The 11.5x forward P/E is a mathematical hallucination unless earnings double overnight, which the 7% revenue growth profile makes impossible. Owls Nest isn't betting on a growth re-rating; they are betting on a buyback-driven EPS floor. The real risk is the 'large payer' churn, not AI-driven margin compression.
"CERIS ROI timing and payer-win visibility, not the P/E math alone, will determine whether CRVL can sustain any re-rating."
Grok, the real flaw in your P/E split is ignoring CERIS ROI timing. If large-payer wins linger or fail to unlock sustained margins, 11.5x forward earnings collapses; a 29x trailing multiple assumes aggressive near-term profitability that isn't guided by 2026 figures. The 'value' rests on tangible ROIC from CERIS, not cash/debt vs. growth, and that visibility is missing. Until ROIC proves, the stock risks re-rating lower on payer-delay risk.
The panel is divided on Owls Nest's CRVL stake, with concerns about AI-driven margin compression, payer deployments, and structural headwinds, but also seeing potential in the debt-free balance sheet and CERIS platform.
Accelerating top-line growth beyond the current single-digit rate through 'large payer wins'
Payer deployments lagging and AI-driven margin uncertainty